Silver Spring-based United Therapeutics Corp. announced Tuesday that it will pay a California company $95 million to develop a new form and delivery method of its flagship Remodulin drug to treat pulmonary arterial hypertension.
{iframe}https://www.bizjournals.com/washington/news/2018/09/04/united-therapeutics-strikes-nine-figure-deal-to.html?ana=e_me_set1&s=newsletter&ed=2018-09-04&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1536077961&j=83625961{/iframe}